Bioject's Distributor Meditrend International Receives Australian Device
Products include the Biojector® 2000, Vial Adapter and Bioject® Zetajet™
TIGARD, Ore., Jan. 22, 2014
TIGARD, Ore., Jan. 22, 2014 /PRNewswire/ --Bioject Medical Technologies Inc.
(OTC Pink: BJCT), a leading developer and manufacturer of needle-free
injection technology, today announced that Meditrend International, Bioject's
Australian/New Zealand Distributorhas received the Australian Register of
Therapeutic Goods Certificate for the Biojector Needle-free injection
Management System (Biojector® 2000), the Vial Transfer Spike and theBioject®
ZetaJet™ Needle-free Injection Therapy System. The Biojector® 2000 is
indicated for delivery of subcutaneous, intramuscular or intradermal
injections of vaccines and other pharmaceutical injectables. The Bioject®
Zetajet™ is indicated for delivery of subcutaneous or intramuscular injections
of vaccines and other injectable drugs into standard injection sites. Both
may be used by healthcare providers and by patients with authorization from
their physicians for prescribed medications.
"We are very pleased that Meditrend International has received registration
for our Biojector® 2000 gas-powered product, the vial adapter and the Bioject®
Zetajet™ our spring-powered product in Australia," said Mark Logomasini,
President and CEO of Bioject. "We are also excited to report that the
agreement has been expanded to include certain islands of the
"We are pleased to have received the Australian registration, as this now
allows us to begin to provide needle-free options to patients and healthcare
providers across Australia," said, Trevor Ekanayake, Managing Partner of
Meditrend International. "As Australia is the major aid and health initiatives
provider to islands of the Pacific, the expansion of the agreement allows
Meditrend's the opportunity to collaborate with healthcare and aid
organisations working across these islands."
About Bioject Medical Technologies Inc.
Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is a
developer and manufacturer of needle-free injection therapy systems (NFITS).
NFITS works by forcing medication at high speed through a tiny orifice held
against the skin. This creates a fine stream of high-pressure fluid able to
penetrate skin and deposit medication in the tissue beneath. To meet global
demand for needle free injection technologies, Bioject is focused on
developing mutually beneficial agreements with leading pharmaceutical,
biotechnology, and veterinary companies, as well as research, global health
and government organizations.
For more information about Bioject, visit www.bioject.com
About Meditrend Australia
Meditrend Australia is a medical device company dedicated to pioneering
innovation and delivering groundbreaking, technologically superior devices to
the Australian and New Zealand medical communities. Based in Melbourne,
Australia, MeditrendInternationalis run by a forward-thinking team with over
three decades of experience in the Australian medical industry.
For more information about Meditrend Australia www.meditrend.com.au
Readers and potential investors are cautioned that an investment in the
Bioject's securities involve an EXTREMELY high degree of risk. Such risks
include, without limitation, the risk that the distribution agreement will not
be successful due to the time required in obtaining government clearances and
the risk that the Company may be unable to comply with the extensive
government regulations applicable to the international business. Bioject (OTC
Pink: BJCT) trades on the OTC Pink tier of the OTC market. Investors can find
Real-Time quotes and market information for the Company on
SOURCE Bioject Medical Technologies Inc.
Contact: Bioject Medical Technologies Inc., Mark Logomasini, President and
CEO, 503-692-8001; Meditrend International, Trevor Ekanayake, Managing
Partner/Director, +61.411 519 104
Press spacebar to pause and continue. Press esc to stop.